Supernus Pharmaceuticals (SUPN) Cash from Investing Activities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash from Investing Activities data on file, last reported at -$19.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 151.5% year-over-year to -$19.2 million in Q1 2026; TTM through Mar 2026 was -$52.4 million, a 48.05% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 102.16% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$19.2 million, up from -$51.3 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for SUPN reached as high as $239.8 million in Q1 2023 and fell as low as -$82.2 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged -$9.0 million across 5 years, with a median of -$30.6 million in 2025.
• Across the five-year window, Cash from Investing Activities sank 1341.65% in 2022 and soared 484.57% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$48.8 million in 2022, then slumped by 35.3% to -$66.0 million in 2023, then soared by 80.85% to -$12.6 million in 2024, then plunged by 306.0% to -$51.3 million in 2025, then soared by 62.55% to -$19.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$19.2 million in Q1 2026, -$51.3 million in Q4 2025, and $48.7 million in Q3 2025.